- Home
- IPW vs HCWB Comparison
IPW vs HCWB Comparison
Compare IPW & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- HCWB
- Stock Information
- Founded
- IPW 2018
- HCWB 2018
- Country
- IPW United States
- HCWB United States
- Employees
- IPW N/A
- HCWB N/A
- Industry
- IPW Catalog/Specialty Distribution
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- HCWB Health Care
- Exchange
- IPW Nasdaq
- HCWB Nasdaq
- Market Cap
- IPW 14.4M
- HCWB 16.1M
- IPO Year
- IPW 2021
- HCWB 2021
- Fundamental
- Price
- IPW $0.61
- HCWB $4.44
- Analyst Decision
- IPW
- HCWB Strong Buy
- Analyst Count
- IPW 0
- HCWB 1
- Target Price
- IPW N/A
- HCWB $35.00
- AVG Volume (30 Days)
- IPW 935.8K
- HCWB 236.1K
- Earning Date
- IPW 05-15-2025
- HCWB 08-13-2025
- Dividend Yield
- IPW N/A
- HCWB N/A
- EPS Growth
- IPW N/A
- HCWB N/A
- EPS
- IPW N/A
- HCWB N/A
- Revenue
- IPW $74,105,251.00
- HCWB $1,445,145.00
- Revenue This Year
- IPW $8.31
- HCWB N/A
- Revenue Next Year
- IPW $77.15
- HCWB N/A
- P/E Ratio
- IPW N/A
- HCWB N/A
- Revenue Growth
- IPW N/A
- HCWB N/A
- 52 Week Low
- IPW $0.41
- HCWB $3.55
- 52 Week High
- IPW $2.36
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- IPW 50.93
- HCWB 28.61
- Support Level
- IPW $0.57
- HCWB $4.05
- Resistance Level
- IPW $0.74
- HCWB $5.77
- Average True Range (ATR)
- IPW 0.11
- HCWB 0.49
- MACD
- IPW -0.00
- HCWB -0.07
- Stochastic Oscillator
- IPW 30.79
- HCWB 9.98
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.